Aardvark Therapeutics宣布,在发现高于目标剂量出现可逆性心脏相关观察结果后,已决定暂停其Hero试验以及开放标签扩展研究。公司强调,该心脏异常现象在停药后具有可逆性,目前正与监管机构密切沟通,进一步评估相关数据以确定后续研究方案。
Aardvark Therapeutics宣布,在发现高于目标剂量出现可逆性心脏相关观察结果后,已决定暂停其Hero试验以及开放标签扩展研究。公司强调,该心脏异常现象在停药后具有可逆性,目前正与监管机构密切沟通,进一步评估相关数据以确定后续研究方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.